tiprankstipranks
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
Company Announcements

Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns

Corvus Pharmaceuticals Inc. (CRVS) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Don't Miss our Black Friday Offers:

Corvus Pharmaceuticals Inc. faces a substantial concentration of power risk, as key insiders and principal stockholders possess around 25% of the company’s outstanding common stock. This significant ownership by executive officers, directors, and major investors grants them considerable influence over corporate decisions, potentially controlling outcomes in matters needing stockholder approval. Their ability to sway elections of directors, organizational changes, or major transactions like mergers could deter or impede any unsolicited buyout offers, possibly undermining the interests of minority shareholders.

The average CRVS stock price target is $5.25, implying 183.78% upside potential.

To learn more about Corvus Pharmaceuticals Inc.’s risk factors, click here.

Related Articles
TheFlyCorvus Pharmaceuticals announces preclinical dataon soquelitinib
TheFlyCorvus Pharmaceuticals price target raised to $13 from $8 at Jefferies
TheFlyCorvus Pharmaceuticals price target raised to $24 from $21 at Ladenburg
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App